<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="t0020">
 <label>Table 4</label>
 <caption>
  <p>Summary of the clinical trials of vaccines for treatment of COVID-19.</p>
 </caption>
 <alt-text id="al0040">Table 4</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center">Sr. no</th>
    <th align="center">Vaccine intervention/treatment</th>
    <th align="center">Sponsor</th>
    <th align="center">Clinical phase
     <break/>(sample size)
    </th>
    <th align="center">Status</th>
    <th align="center">Clinical trial identifier</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>1.</td>
    <td>INO-4800, a Prophylactic Vaccine; Intradermally</td>
    <td align="center">Inovio Pharmaceuticals, USA</td>
    <td align="center">Phase I
     <break/>(40)
    </td>
    <td align="center">On-going</td>
    <td align="center">
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04336410" id="ir0405" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04336410</ext-link>
    </td>
   </tr>
   <tr>
    <td>2.</td>
    <td>2019-nCoV Vaccine (mRNA-1273)
     <break/>Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV
    </td>
    <td align="center">National Institute of Allergy and Infectious Diseases (NIAID), USA</td>
    <td align="center">Phase I
     <break/>(45)
    </td>
    <td align="center">Completed</td>
    <td align="center">
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04283461" id="ir0410" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04283461</ext-link>
    </td>
   </tr>
   <tr>
    <td>3.</td>
    <td>Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18Â Years and Older</td>
    <td align="center">Moderna TX, Inc.</td>
    <td align="center">Phase II
     <break/>(600)
    </td>
    <td align="center">On-going</td>
    <td align="center">
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04405076" id="ir0415" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04405076</ext-link>
    </td>
   </tr>
   <tr>
    <td>4.</td>
    <td>Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates (BNT162a1, BNT162b1, BNT162b2 and BNT162c2) against COVID-19 in Healthy Adults</td>
    <td align="center">Biontech SE
     <break/>Pfizer
    </td>
    <td align="center">Phase I
     <break/>(7600)
    </td>
    <td align="center">Completed</td>
    <td align="center">
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04368728" id="ir0420" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04368728</ext-link>
    </td>
   </tr>
   <tr>
    <td>5.</td>
    <td>A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults</td>
    <td align="center">Biontech RNA Pharmaceuticals GmbH</td>
    <td align="center">Phase1 &amp;II
     <break/>(200)
    </td>
    <td align="center">On-going</td>
    <td align="center">
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04380701" id="ir0425" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04380701</ext-link>
    </td>
   </tr>
   <tr>
    <td>6.</td>
    <td>Pathogen-specific aAPC; Subcutaneously</td>
    <td align="center">Shenzhen Geno-Immune Medical Institute, Guangdong, China</td>
    <td align="center">Phase I
     <break/>(100)
    </td>
    <td align="center">On-going</td>
    <td align="center">
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04299724" id="ir0430" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04299724</ext-link>
    </td>
   </tr>
   <tr>
    <td>7.</td>
    <td>Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus; Subcutaneously</td>
    <td align="center">Shenzhen Geno-Immune Medical Institute, Guangdong, China</td>
    <td align="center">Phase I &amp;II
     <break/>(100)
    </td>
    <td align="center">On-going</td>
    <td align="center">
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04276896" id="ir0435" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04276896</ext-link>
    </td>
   </tr>
   <tr>
    <td>8.</td>
    <td>BCG Vaccine for Covid-19; Intracutaneously</td>
    <td align="center">UMC Utrecht, Netherland</td>
    <td align="center">Phase III
     <break/>(1500)
    </td>
    <td align="center">On-going</td>
    <td align="center">
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04328441" id="ir0440" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04328441</ext-link>
    </td>
   </tr>
   <tr>
    <td>9.</td>
    <td>SARS-CoV-2 Inactivated Vaccine</td>
    <td align="center">Sinovac Biotech Co., Ltd., Jiangsu, China</td>
    <td align="center">Phase I (Medium Dose, 144)
     <break/>Phase II (High Dose, 600)
    </td>
    <td align="center">On-going</td>
    <td align="center">
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04352608" id="ir0445" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04352608</ext-link>
    </td>
   </tr>
   <tr>
    <td>10.</td>
    <td>BCG Vaccine for Covid-19; Intradermally</td>
    <td align="center">Murdoch Children's Research Institute, Victoria, Australia
     <break/>
    </td>
    <td align="center">Phase III
     <break/>(4170)
    </td>
    <td align="center">On-going</td>
    <td align="center">
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04327206" id="ir0450" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04327206</ext-link>
    </td>
   </tr>
   <tr>
    <td>11.</td>
    <td>Coronavirus Disease (COVID-19) vaccine
     <break/>ChAdOx1 nCoV-19
    </td>
    <td align="center">University of Oxford, United Kingdom</td>
    <td align="center">Phase I &amp; II
     <break/>(1090)
    </td>
    <td align="center">Completed</td>
    <td align="center">
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04324606" id="ir0455" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04324606</ext-link>
    </td>
   </tr>
   <tr>
    <td>12.</td>
    <td>Investigating a Vaccine Against COVID-19</td>
    <td align="center">University of Oxford, United Kingdom</td>
    <td align="center">Phase II &amp; III
     <break/>(10260)
    </td>
    <td align="center">On-going</td>
    <td align="center">
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04400838" id="ir0460" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04400838</ext-link>
    </td>
   </tr>
   <tr>
    <td>13.</td>
    <td>Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)</td>
    <td align="center">CanSino Biologics Inc.</td>
    <td align="center">Phase I
     <break/>(108)
    </td>
    <td align="center">Completed</td>
    <td align="center">
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04313127" id="ir0465" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04313127</ext-link>
    </td>
   </tr>
   <tr>
    <td>14.</td>
    <td>A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) (CTII-nCoV)</td>
    <td align="center">CanSino Biologics Inc.
     <break/>Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China
    </td>
    <td align="center">Phase II
     <break/>(508)
    </td>
    <td align="center">On-going</td>
    <td align="center">
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04341389" id="ir0470" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04341389</ext-link>
    </td>
   </tr>
   <tr>
    <td>15.</td>
    <td>Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant</td>
    <td align="center">Novavax</td>
    <td align="center">Phase I
     <break/>(131)
    </td>
    <td align="center">On-going</td>
    <td align="center">
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04368988" id="ir0475" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04368988</ext-link>
    </td>
   </tr>
   <tr>
    <td>16.</td>
    <td>Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19)</td>
    <td align="center">Sinovac Research and Development Co., Ltd.</td>
    <td align="center">Phase I
     <break/>(72)
     <break/>Phase II
     <break/>(350)
    </td>
    <td align="center">On-going</td>
    <td align="center">
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04383574" id="ir0480" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04383574</ext-link>
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
